These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36482326)

  • 61. Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial.
    Shahbaznejad L; Davoudi A; Eslami G; Markowitz JS; Navaeifar MR; Hosseinzadeh F; Movahedi FS; Rezai MS
    Clin Ther; 2021 Jun; 43(6):1007-1019. PubMed ID: 34052007
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Zhu F; Zhuang C; Chu K; Zhang L; Zhao H; Huang S; Su Y; Lin H; Yang C; Jiang H; Zang X; Liu D; Pan H; Hu Y; Liu X; Chen Q; Song Q; Quan J; Huang Z; Zhong G; Chen J; Han J; Sun H; Cui L; Li J; Chen Y; Zhang T; Ye X; Li C; Wu T; Zhang J; Xia NS
    Lancet Respir Med; 2022 Aug; 10(8):749-760. PubMed ID: 35644168
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol.
    Mera-Cordero F; Bonet-Monne S; Almeda-Ortega J; García-Sangenís A; Cunillera-Puèrtolas O; Contreras-Martos S; Alvarez-Muñoz G; Monfà R; Balanzo-Joué M; Morros R; Salvador-Gonzalez B
    Trials; 2022 Jan; 23(1):19. PubMed ID: 34991703
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study).
    Kinoshita T; Shinoda M; Nishizaki Y; Shiraki K; Hirai Y; Kichikawa Y; Tsushima K; Shinkai M; Komura N; Yoshida K; Kido Y; Kakeya H; Uemura N; Kadota J
    BMC Med; 2022 Sep; 20(1):342. PubMed ID: 36163020
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial.
    Aricò E; Castiello L; Bracci L; Urbani F; Lombardo F; Bacigalupo I; Ancidoni A; Vanacore N; Falcione A; Reggiani C; Dutti GM; Maglie MG; Papa O; Bartoletti PL; Ozzella G; Bevilacqua N; Nicastri E; Belardelli F; Sconocchia G
    Trials; 2021 Sep; 22(1):584. PubMed ID: 34479601
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial".
    Tornero C; Vallejo R; Cedeño D; Orduña J; Pastor E; Belaouchi M; Escamilla B; Laredo M; Del Mar Garzando M
    Trials; 2020 Jun; 21(1):576. PubMed ID: 32586395
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
    Montgomery H; Hobbs FDR; Padilla F; Arbetter D; Templeton A; Seegobin S; Kim K; Campos JAS; Arends RH; Brodek BH; Brooks D; Garbes P; Jimenez J; Koh GCKW; Padilla KW; Streicher K; Viani RM; Alagappan V; Pangalos MN; Esser MT;
    Lancet Respir Med; 2022 Oct; 10(10):985-996. PubMed ID: 35688164
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.
    García IG; Rodriguez-Rubio M; Mariblanca AR; de Soto LM; García LD; Villatoro JM; Parada JQ; Meseguer ES; Rosales MJ; González J; Arribas JR; Carcas AJ; de la Oliva P; Borobia AM
    Trials; 2020 Jun; 21(1):466. PubMed ID: 32493475
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study.
    Abd-Elsalam S; Noor RA; Badawi R; Khalaf M; Esmail ES; Soliman S; Abd El Ghafar MS; Elbahnasawy M; Moustafa EF; Hassany SM; Medhat MA; Ramadan HK; Eldeen MAS; Alboraie M; Cordie A; Esmat G
    J Med Virol; 2021 Oct; 93(10):5833-5838. PubMed ID: 34076901
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.
    Wada T; Hibino M; Aono H; Kyoda S; Iwadate Y; Shishido E; Ikeda K; Kinoshita N; Matsuda Y; Otani S; Kameda R; Matoba K; Nonaka M; Maeda M; Kumagai Y; Ako J; Shichiri M; Naoki K; Katagiri M; Takaso M; Iwamura M; Katayama K; Miyatsuka T; Orihashi Y; Yamaoka K;
    Front Med (Lausanne); 2023; 10():1139046. PubMed ID: 37283627
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.
    Bravo L; Smolenov I; Han HH; Li P; Hosain R; Rockhold F; Clemens SAC; Roa C; Borja-Tabora C; Quinsaat A; Lopez P; López-Medina E; Brochado L; Hernández EA; Reynales H; Medina T; Velasquez H; Toloza LB; Rodriguez EJ; de Salazar DIM; Rodríguez CA; Sprinz E; Cerbino-Neto J; Luz KG; Schwarzbold AV; Paiva MS; Carlos J; Montellano MEB; de Los Reyes MRA; Yu CY; Alberto ER; Panaligan MM; Salvani-Bautista M; Buntinx E; Hites M; Martinot JB; Bhorat QE; Badat A; Baccarini C; Hu B; Jurgens J; Engelbrecht J; Ambrosino D; Richmond P; Siber G; Liang J; Clemens R
    Lancet; 2022 Jan; 399(10323):461-472. PubMed ID: 35065705
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.
    Halperin SA; Ye L; MacKinnon-Cameron D; Smith B; Cahn PE; Ruiz-Palacios GM; Ikram A; Lanas F; Lourdes Guerrero M; Muñoz Navarro SR; Sued O; Lioznov DA; Dzutseva V; Parveen G; Zhu F; Leppan L; Langley JM; Barreto L; Gou J; Zhu T;
    Lancet; 2022 Jan; 399(10321):237-248. PubMed ID: 34953526
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The efficacy of Siddha Medicine, Kabasura Kudineer (KSK) compared to Vitamin C & Zinc (CZ) supplementation in the management of asymptomatic COVID-19 cases: A structured summary of a study protocol for a randomised controlled trial.
    Natarajan S; Anbarasi C; Sathiyarajeswaran P; Manickam P; Geetha S; Kathiravan R; Prathiba P; Pitchiahkumar M; Parthiban P; Kanakavalli K; Balaji P
    Trials; 2020 Oct; 21(1):892. PubMed ID: 33109252
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
    Goepfert PA; Fu B; Chabanon AL; Bonaparte MI; Davis MG; Essink BJ; Frank I; Haney O; Janosczyk H; Keefer MC; Koutsoukos M; Kimmel MA; Masotti R; Savarino SJ; Schuerman L; Schwartz H; Sher LD; Smith J; Tavares-Da-Silva F; Gurunathan S; DiazGranados CA; de Bruyn G
    Lancet Infect Dis; 2021 Sep; 21(9):1257-1270. PubMed ID: 33887209
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective?
    Nabi-Afjadi M; Mohebi F; Zalpoor H; Aziziyan F; Akbari A; Moradi-Sardareh H; Bahreini E; Moeini AM; Effatpanah H
    Inflammopharmacology; 2023 Feb; 31(1):21-35. PubMed ID: 36609716
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV).
    Schilling WHK; Jittamala P; Watson JA; Ekkapongpisit M; Siripoon T; Ngamprasertchai T; Luvira V; Pongwilai S; Cruz C; Callery JJ; Boyd S; Kruabkontho V; Ngernseng T; Tubprasert J; Abdad MY; Piaraksa N; Suwannasin K; Hanboonkunupakarn P; Hanboonkunupakarn B; Sookprome S; Poovorawan K; Thaipadungpanit J; Blacksell S; Imwong M; Tarning J; Taylor WRJ; Chotivanich V; Sangketchon C; Ruksakul W; Chotivanich K; Teixeira MM; Pukrittayakamee S; Dondorp AM; Day NPJ; Piyaphanee W; Phumratanaprapin W; White NJ;
    Elife; 2023 Feb; 12():. PubMed ID: 36803992
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.